Autism Speaks recently hosted the first scientific leadership conference on research into the safety and potential benefits of cannabis-based medicines for autism and its associated medical conditions.

The two-day meeting, in New York City, brought together more than 30 leading researchers, government regulators and members of the autism community.

“Our focus is on understanding the scope of early research and regulatory issues,” says Autism Speaks Chief Science Officer Thomas Frazier. “Our goal is to develop consensus and guidance for the next steps in this emerging field.”